Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compnyâs lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
äŒæ¥ã³ãŒãDYAI
äŒç€ŸåDyadic International Inc
äžå Žæ¥Nov 05, 2004
æé«çµå¶è²¬ä»»è
ãCEOãEmalfarb (Mark A)
åŸæ¥å¡æ°6
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Nov 05
æ¬ç€Ÿæåšå°1044 North U.S. Highway One
éœåžJUPITER
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·33477
é»è©±çªå·15617438333
ãŠã§ããµã€ãhttps://dyadic.com/
äŒæ¥ã³ãŒãDYAI
äžå Žæ¥Nov 05, 2004
æé«çµå¶è²¬ä»»è
ãCEOãEmalfarb (Mark A)